biote Corp. (BTMD) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-06

Key Insights

Q1 2026 earnings announcement filed on May 6, 2026 for the quarter ended March 31, 2026, indicating timely financial reporting and adherence to SEC disclosure requirements.
Company maintains emerging growth company status, allowing potential benefits from scaled regulatory compliance and extended transition periods for accounting standards, which may reduce near-term compliance costs.
Press release details are furnished but not filed, limiting legal liability exposure under Section 18 of the Exchange Act and suggesting management is exercising cautious disclosure practices.

Want the newest filings?

This analysis covers the filing from 2026-05-06. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-04-03

biote Corp. has filed an 8-K report disclosing the posting of its updated Investor Presentation on the company's website.
The Investor Presentation likely contains important information about the company's financial performance, business strategy, and other key developments.
Investors should review the Investor Presentation for any material updates or changes that could impact the company's outlook and investment thesis.

Filed: 2026-03-11

biote Corp. reported its financial results for the fourth quarter and fiscal year ended December 31, 2025, indicating the company's financial performance over the past year.
The company is an emerging growth company, which means it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies.
Investors should review the company's press release and financial statements to assess the company's financial condition, results of operations, and any material events or developments.

Filed: 2026-01-26

biote Corp. has initiated a voluntary recall of specific hormone pellet lots due to potential metal particulate matter contamination, which will result in a one-time charge of approximately $1.3M in the fourth quarter.
The recall is not expected to significantly impact biote's ability to supply pellets to its practitioner partners or their ability to serve patients, but the company may incur additional costs of around $1.0M in 2026 related to the recall.
The company does not believe its fourth quarter business was impacted beyond the inventory write-off, and it will provide more details on the financial impact when reporting its Q4 results.

Other reports for biote Corp.

Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.